REPLIMUNE GROUP, INC. (REPL) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 94.22M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 94.22M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 94.22M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 94.22M | (m) | (m) |
| 2025-12-31 | 82.57M | (m) | (m) |
| 2025-09-30 | 78.44M | (m) | (m) |
| 2025-06-30 | 78.06M | (m) | (m) |
| 2024-12-31 | 77.01M | (m) | (m) |
| 2024-09-30 | 68.42M | (m) | (m) |
| 2024-06-30 | 68.32M | (m) | (m) |
| 2024-03-31 | 61.42M | (m) | (m) |
| 2023-12-31 | 61.39M | (m) | (m) |
| 2023-09-30 | 59.06M | (m) | (m) |
| 2023-06-30 | 59.00M | (m) | (m) |
| 2023-03-31 | 57.78M | (m) | (m) |
| 2022-12-31 | 56.65M | (m) | (m) |
| 2022-09-30 | 49.74M | (m) | (m) |
| 2022-06-30 | 49.31M | (m) | (m) |
| 2021-12-31 | 47.21M | (m) | (m) |
| 2021-09-30 | 46.89M | (m) | (m) |
| 2021-06-30 | 46.77M | (m) | (m) |
| 2020-12-31 | 46.49M | (m) | (m) |
| 2020-09-30 | 45.96M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |